Visceral fat reduction
A novel approach for reducing visceral fat and improving sleep quality in obese adults
The study
An early-stage, placebo-controlled, triple-blinded trial in 24 adults aged 46–59 with a BMI of 30–35. For 60 days, participants took a placebo or a 2 mg or 5 mg Pep-19 capsule once daily at bedtime.
Key findings
- The 5 mg group lost about 17% of its visceral fat, the high-risk fat stored around the organs.
- Participants reported improved sleep quality.
- Pep-19 was well tolerated, with no adverse effects reported.